Search research articles
Contact Us
Filters
Showing results (21-30 of 77) with videos related to
Page
of 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 2005
Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial
Simon C Crawford, Paul A Vasey, Jim Paul, et al.
Cancer Treatment Reviews
|
October 7, 2016
Trabectedin as a chemotherapy option for patients with BRCA deficiency
Bradley J Monk, Domenica Lorusso, Antoine Italiano, et al.
The Lancet. Oncology
|
November 3, 2007
Bleomycin and scuba diving: where is the harm?
Ronald de Wit, Stefan Sleijfer, Stan B Kaye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2007
The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin
James Witham, Melanie R Valenti, Alexis K De-Haven-Brandon, et al.
Cancer Journal (Sudbury, Mass.)
|
October 15, 2009
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development
Daniel S W Tan, George V Thomas, Michelle D Garrett, et al.
Radiology
|
August 11, 2011
Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging--value of histogram analysis of apparent diffusion coefficients
Stavroula Kyriazi, David J Collins, Christina Messiou, et al.
Investigational New Drugs
|
October 8, 2010
Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors
Laura Vidal, Margarita Magem, Clare Barlow, et al.
Journal of the National Cancer Institute
|
November 18, 2004
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma
Paul A Vasey, Gordon C Jayson, Alan Gordon, et al.
Cancer Chemotherapy and Pharmacology
|
November 12, 2010
Clinical benefit of early phase clinical trial participation for advanced sarcoma patients
Robin L Jones, David Olmos, Khin Thway, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 26, 2012
Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer
David S P Tan, Timothy A Yap, Margaret Hutka, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 77) with videos related to
Sort By:
Page
of 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 2005
Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial
Simon C Crawford, Paul A Vasey, Jim Paul, et al.
Cancer Treatment Reviews
|
October 7, 2016
Trabectedin as a chemotherapy option for patients with BRCA deficiency
Bradley J Monk, Domenica Lorusso, Antoine Italiano, et al.
The Lancet. Oncology
|
November 3, 2007
Bleomycin and scuba diving: where is the harm?
Ronald de Wit, Stefan Sleijfer, Stan B Kaye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2007
The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin
James Witham, Melanie R Valenti, Alexis K De-Haven-Brandon, et al.
Cancer Journal (Sudbury, Mass.)
|
October 15, 2009
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development
Daniel S W Tan, George V Thomas, Michelle D Garrett, et al.
Radiology
|
August 11, 2011
Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging--value of histogram analysis of apparent diffusion coefficients
Stavroula Kyriazi, David J Collins, Christina Messiou, et al.
Investigational New Drugs
|
October 8, 2010
Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors
Laura Vidal, Margarita Magem, Clare Barlow, et al.
Journal of the National Cancer Institute
|
November 18, 2004
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma
Paul A Vasey, Gordon C Jayson, Alan Gordon, et al.
Cancer Chemotherapy and Pharmacology
|
November 12, 2010
Clinical benefit of early phase clinical trial participation for advanced sarcoma patients
Robin L Jones, David Olmos, Khin Thway, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 26, 2012
Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer
David S P Tan, Timothy A Yap, Margaret Hutka, et al.
Page
of 8